Skip to content

ImGTS for Patients With Behavioral and Psychological Symptoms of Dementia (Phase 2)

Developing Immersive Gamification Technology Systems for the Management of Patients With Alzheimer's Disease With Behavioral and Psychological Symptoms of Dementia (Phase 2 Trial)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06072014
Enrollment
30
Registered
2023-10-10
Start date
2023-07-10
Completion date
2023-12-31
Last updated
2023-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia Alzheimers

Brief summary

The proposed research project aims to answer the question Are immersive technology systems effective in the management and treatment of patients with BPSD?. This project is composed of three phases and the current study is the second phase. The phase 2 trial aims to create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its clinical effectiveness, safety, usability, and acceptability among patients with mild to moderate Alzheimer's disease.

Interventions

OTHERVirtual reality

A role-playing game with activities based on existing therapy activities (such as orientation therapy, reminiscence therapy, art therapy, and music therapy) that are used to manage behavioral and psychological symptoms of dementia

Sponsors

Augmented eXperience E-health Laboratory
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 60 years old or older * Diagnosed with mild to moderate Alzheimer's dementia according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria * Montreal Cognitive Assessment-Philippines (MOCA-P) score of 10-20 inclusive * Neuropsychiatric Inventory (NPI-12) score 1-50 inclusive * Reisberg Scale Stage 4-5 inclusive * Stable dose of antidepressants for the past 6 weeks * Stable dose of antipsychotics for the past 4 weeks * Able to walk unassisted or with minimal assistance, with or without assistive device * No other explanation for condition based on reasonable clinical diagnostics

Exclusion criteria

* Have mild cognitive impairment (no dementia) * Have MOCA-P score less than 10 or more than 20 * Other non-amnestic dementia syndromes * Have receptive aphasia * Have significant visual or hearing impairment * Have an active psychiatric disorder prior to Alzheimer dementia diagnosis * Had previous episodes of seizures, diagnosis of epilepsy, or intake of antiepileptic or seizure medications * Have quadriplegia or paralysis of the dominant hand * Have a history of motion sickness * Experience claustrophobia * Have a diagnosis of a terminal illness or a life expectancy of less than one year

Design outcomes

Primary

MeasureTime frameDescription
Usability of the virtual reality intervention will be assessed using the System Usability ScaleImmediately after each intervention, within an hour of completion of the virtual reality gameThe SUS is a 10-item questionnaire that is widely used in the evaluation of various kinds and aspects of technology. Each question has five response options ranging from 'Strongly agree' to 'Strongly disagree', which has a corresponding number value. Each response is added and multiplied by 2.5 to obtain the final score that ranges from 0 to 100. A SUS score above 68 is considered above average.
Incidence of behavioral and psychological symptoms of dementia will be assessed using the Neuropsychiatric Inventory-12Within one hour after completion of the fourth sessionThe NPI evaluates the degree and severity of BPSDs and the distress it causes the primary caregiver. Scores range from 0 to 120 where higher scores indicate greater psychiatric disturbance.
Incidence of virtual reality sickness symptoms will be assessed using the Virtual Reality Sickness QuestionnaireImmediately after each intervention, within an hour of completion of the virtual reality gameThe VRSQ will measure a participant's experience with the following symptoms: general discomfort, fatigue, eye strain, difficulty focusing, headache, fullness of head, blurring of vision, dizziness (when eyes are closed), and vertigo. Symptoms will be rated on a 4-point scale: 0 or None, 1 or Slight, 2 or Moderate, and 3 or Severe.

Secondary

MeasureTime frameDescription
Cognitive function will be assessed using ADAS-CogWithin one hour after completion of the fourth sessionThe cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) is an 11-item tool for the assessment of the following tasks: word recall, naming objects and fingers, commands, constructional praxis, ideational praxis, orientation, word recognition, and language.
Health-related quality of life will be assessed using DEMQOLWithin one hour after completion of the fourth sessionThe Health-related quality of life for people with dementia (DEMQOL) is a 28-item self-report measure of quality of life specific for persons with mild-to-moderate dementia. It covers four dimensions of quality of life, namely, daily activities, memory, negative emotion, and positive emotion.
Activities of daily living will be assessed using ADCS-ADLWithin one hour after completion of the fourth sessionThe Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) is a 24-item assessment on activities of daily living within the past four weeks
Cognitive function will be assessed using MOCA-PWithin one hour after completion of the fourth sessionMontreal Cognitive Assessment-Philippines (MOCA-P) is a 30-item test that takes about 10-12 minutes to complete. The test measures different cognitive domains such as visuospatial/executive, naming, memory, attention, language, abstraction, and orientation.
Cognitive function will be assessed using MMSEWithin one hour after completion of the fourth sessionThe Mini-Mental State Exam (MMSE) is a 30-item test for cognitive function. It assesses attention, orientation, memory, registration, recall, calculation, language, and an individual's ability to draw a complex polygon.

Other

MeasureTime frameDescription
AcceptabilityWithin one day after completing virtual reality experienceAcceptability will be measured among a small group of patients and their caregivers through an interview and a focus group discussion

Countries

Philippines

Contacts

Primary ContactRoland Dominic G. Jamora, MD, PhD
rgjamora@up.edu.ph+639985438062

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026